These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35105861)

  • 1. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
    Khadka P; Reitman ZJ; Lu S; Buchan G; Gionet G; Dubois F; Carvalho DM; Shih J; Zhang S; Greenwald NF; Zack T; Shapira O; Pelton K; Hartley R; Bear H; Georgis Y; Jarmale S; Melanson R; Bonanno K; Schoolcraft K; Miller PG; Condurat AL; Gonzalez EM; Qian K; Morin E; Langhnoja J; Lupien LE; Rendo V; Digiacomo J; Wang D; Zhou K; Kumbhani R; Guerra Garcia ME; Sinai CE; Becker S; Schneider R; Vogelzang J; Krug K; Goodale A; Abid T; Kalani Z; Piccioni F; Beroukhim R; Persky NS; Root DE; Carcaboso AM; Ebert BL; Fuller C; Babur O; Kieran MW; Jones C; Keshishian H; Ligon KL; Carr SA; Phoenix TN; Bandopadhayay P
    Nat Commun; 2022 Feb; 13(1):604. PubMed ID: 35105861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
    Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
    Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
    Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS
    Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
    Jansen S; Geuer S; Pfundt R; Brough R; Ghongane P; Herkert JC; Marco EJ; Willemsen MH; Kleefstra T; Hannibal M; Shieh JT; Lynch SA; Flinter F; FitzPatrick DR; Gardham A; Bernhard B; Ragge N; Newbury-Ecob R; Bernier R; Kvarnung M; Magnusson EA; Wessels MW; van Slegtenhorst MA; Monaghan KG; de Vries P; Veltman JA; ; Lord CJ; Vissers LE; de Vries BB
    Am J Hum Genet; 2017 Apr; 100(4):650-658. PubMed ID: 28343630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases.
    El Ayoubi R; Boisselier B; Rousseau A
    J Neurooncol; 2017 Sep; 134(2):465-467. PubMed ID: 28589424
    [No Abstract]   [Full Text] [Related]  

  • 9. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
    Burocziova M; Burdova K; Martinikova AS; Kasparek P; Kleiblova P; Danielsen SA; Borecka M; Jenikova G; Janečková L; Pavel J; Zemankova P; Schneiderova M; Schwarzova L; Ticha I; Sun XF; Jiraskova K; Liska V; Vodickova L; Vodicka P; Sedlacek R; Kleibl Z; Lothe RA; Korinek V; Macurek L
    Cell Death Dis; 2019 Oct; 10(11):818. PubMed ID: 31659152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
    Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
    Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
    Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
    Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
    Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
    Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
    Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
    Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPM1D activity promotes cellular transformation by preventing senescence and cell death.
    Stoyanov M; Martinikova AS; Matejkova K; Horackova K; Zemankova P; Burdova K; Zemanova Z; Kleiblova P; Kleibl Z; Macurek L
    Oncogene; 2024 Oct; 43(42):3081-3093. PubMed ID: 39237765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
    Miller PG; Sperling AS; Mayerhofer C; McConkey ME; Ellegast JM; Da Silva C; Cohen DN; Wang C; Sharda A; Yan N; Saha S; Schluter C; Schechter I; Słabicki M; Sandoval B; Kahn J; Boettcher S; Gibson CJ; Scadden DT; Stegmaier K; Bhatt S; Lindsley RC; Ebert BL
    Blood; 2023 Dec; 142(24):2079-2091. PubMed ID: 37595362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
    Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
    Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma.
    Georgescu MM; Islam MZ; Li Y; Circu ML; Traylor J; Notarianni CM; Kline CN; Burns DK
    Acta Neuropathol Commun; 2020 Jul; 8(1):111. PubMed ID: 32680567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
    Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
    Lu X; Nguyen TA; Donehower LA
    Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.